Terns Pharmaceuticals

Yahoo Finance • 16 days ago

Terns Pharmaceuticals (TERN) Eyes Expansion Beyond China Amid Strong Analyst Sentiment

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is included in our list of the 11 Best Performing Stocks in the Last 12 Months.Terns Pharmaceuticals (TERN) Eyes Expansion Beyond China Amid Strong Analyst Sentiment On January 16, 2026, Terns Pha... Full story

Yahoo Finance • 2 months ago

Terns Pharmaceuticals (TERN) Climbs 53% on Stellar Leukemia Treatment Trial

We recently published 10 Stocks Delivering Explosive 18-190% Gains. Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the last week’s heavy gainers. Terns Pharmaceuticals soared by 53 percent in just the past five trading days of the we... Full story

Yahoo Finance • 2 months ago

Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the closing of its previously announced underwritten public... Full story

Yahoo Finance • 2 months ago

Terns Announces Pricing of Upsized $650 Million Public Offering

FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the pricing of its upsized underwritten public offering of 1... Full story

Yahoo Finance • 2 months ago

Terns Announces Proposed Public Offering

FOSTER CITY, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has commenced a proposed underwritten public offerin... Full story

Yahoo Finance • 2 months ago

Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701’s Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting

64% MMR achievement by 24 weeks across all efficacy evaluable patients 75% MMR achievement by 24 weeks in efficacy evaluable patients at doses >320mg QD Encouraging safety/tolerability profile maintained with longer duration of treatment... Full story

Yahoo Finance • 2 months ago

These stocks are new additions to Mizuho’s ’Americas Top Picks’ list

Investing.com -- Mizuho has refreshed its monthly Americas Top Picks list, adding new high-conviction ideas selected by its U.S. equity analysts. The list highlights “our analysts’ highest conviction, catalyst-driven ideas,” Mizuho says,... Full story

Yahoo Finance • 3 months ago

Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors

Key Points New York City-based Commodore Capital initiated a stake of 5.7 million shares of Terns Pharmaceuticals in the third quarter, an increase of $42.8 million in position value. The new position represents 2.1% of 13F reportable ass... Full story

Yahoo Finance • 3 months ago

William Blair Reiterates a Buy on Terns Pharmaceuticals (TERN)

​Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is one of the Hottest Small Cap Stocks to Buy Now. On November 11, Andy Hsieh from William Blair reiterated a Buy rating on Terns Pharmaceuticals, Inc. (NASDAQ:TERN) without disclosing any price t... Full story

Yahoo Finance • 3 months ago

Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London

FOSTER CITY, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of senior management will be presenting at the... Full story

Yahoo Finance • 3 months ago

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

FOSTER CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of November 1, 2025 equity inducement... Full story

Yahoo Finance • 4 months ago

Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting

Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient population Encouraging safety and tolerability profile at all doses evaluated Company to host investor update call on December 8th at 4:... Full story

Yahoo Finance • 4 months ago

Terns falls as phase 2 data on oral GLP-1 obesity asset disappoints

[A red arrow, probably from a computer chart, pointing down.] mattjeacock * Terns Pharmaceuticals (NASDAQ:TERN [https://seekingalpha.com/symbol/TERN]) is down ~14% in after-hours trading Tuesday after saying it would abandon its oral GL... Full story

Yahoo Finance • 4 months ago

Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity

Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse events Asymptomatic, reversible grade 3 liver enzyme elevations occurred in three participants during post-treatment follow-up per... Full story

Yahoo Finance • 5 months ago

2 Under-the-Radar Stocks That Could Soar

Key Points Terns Pharmaceuticals and Rhythm Pharmaceuticals are developing weight loss medicines. Terns Pharmaceuticals has an upcoming data readout for a promising oral candidate. Rhythm Pharmaceuticals is targeting label expansions for... Full story

Yahoo Finance • 5 months ago

SA Asks: Which biotechs could be acquired by year's end?

[word m and a made with wood building blocks, stock image] Maksim Labkouski The fourth quarter has historically been a busy time for the biopharma industry, with the sector generally seeing a significant uptick in M&A activity. We asked... Full story

Yahoo Finance • 6 months ago

Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025

FOSTER CITY, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to addre... Full story

Yahoo Finance • 6 months ago

Terns Pharmaceuticals’ SWOT analysis: obesity drug stock poised for pivotal data

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and other metabolic diseases. The company’s stock has garnered significant attention from analysts and inv... Full story

Yahoo Finance • 6 months ago

Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors

On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns Pharmaceuticals, Inc. (NASDAQ:TERN), Viking Therapeutics Inc. (NASDAQ:VKTX), and Structure Therapeutics Inc. (NASDAQ... Full story

Yahoo Finance • 6 months ago

Terns (TERN) Q2 Net Loss Narrows 16%

Key Points Net loss per share for Q2 2025 was $(0.26). No revenue reported as Terns remains a clinical-stage, pre-commercial biotech. A strong cash position of $315.4 million as of Q2 2025 is expected to fund operations into 2028.These 10... Full story